Group 1 - The company will hold its first extraordinary general meeting of 2025 on September 8, 2025, with both on-site and online voting options available for shareholders [2][5][8] - The meeting will discuss various resolutions, including the appointment of a new director, and will require shareholder approval [31][32] - Shareholders can participate in the voting through the Shanghai Stock Exchange's network voting system, with specific timeframes for both online and on-site voting [2][5][8] Group 2 - The company reported that from July 1 to July 31, 2025, a total of 253,760 shares were exercised under the 2021 stock option incentive plan, representing 10.02% of the total options available [16][28] - Cumulatively, as of July 31, 2025, 9,413,280 stock options have been exercised, accounting for 62.76% of the total granted options, generating approximately 46.88 million yuan in funds for the company [28][29] - The total share capital increased from 384,293,875 shares to 384,547,635 shares due to the exercised options, but this did not significantly impact the company's financial status [29][30] Group 3 - The company announced the cancellation of its supervisory board and the revision of its articles of association and related rules to enhance governance and compliance with new regulations [43][44] - The responsibilities of the supervisory board will be transferred to the audit committee of the board of directors, ensuring continued oversight of the company's operations [43][44] - The company expressed gratitude for the contributions of the supervisory board members during their tenure [44]
新疆百花村医药集团股份有限公司2025年半年度报告摘要